Skip to main
  1. Stocks
  2. Scholar Rock Holding Corp
  3. Forecast
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding is benefiting from a first FDA approval that validates its core science and materially de-risks the platform, with SAPPHIRE showing a clinically meaningful 2.2-point HFMSE improvement and ~98% of treated patients continuing into ONYX. The approved label is broad across SMA subtypes and ambulatory status, covering nearly 6,600 U.S. patients on SMN2-targeting therapy, while management’s expected roughly $310K of annual net revenue per typical patient and $11,659 WAC per 150-mg vial support a sizable launch opportunity. Concerns around fracture and reproductive language appear unlikely to meaningfully curtail uptake, especially given high physician enthusiasm, no contraindication, and the company’s expansion potential through subcutaneous apitegromab, SRK-439, and other neuromuscular programs.

Bears say

Scholar Rock Holding is viewed negatively because its lead opportunity faces payer duration risk, with insurers potentially treating Isembyld differently from SMN modifiers since it does not preserve motor neurons. The SAPPHIRE motor-scale gains were described as being on the smaller end of significance, and a roughly 2-point improvement may not justify monthly IV infusions for many patients, especially older and more stable ones. Additional downside comes from the possibility of unexpected real-world safety issues, an adverse EC regulatory decision for European sales, and pricing reform that could pressure reimbursement for rare disease products.

SRRK has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

SRRK Analyst Forecast & Price Prediction

Get the latest SRRK stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SRRK

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 13 analysts, SRRK has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


SRRK Analyst Forecast & Price Prediction

Get the latest SRRK stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SRRK

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SRRK stock data and trends